X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs STRIDES PHARMA SCIENCE - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER STRIDES PHARMA SCIENCE PFIZER/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 34.1 69.1 49.4% View Chart
P/BV x 5.4 1.2 461.5% View Chart
Dividend Yield % 0.6 0.4 152.0%  

Financials

 PFIZER   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    PFIZER
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
PFIZER/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs2,3651,147 206.2%   
Low Rs1,625642 253.1%   
Sales per share (Unadj.) Rs430.3317.2 135.6%  
Earnings per share (Unadj.) Rs78.77.8 1,003.3%  
Cash flow per share (Unadj.) Rs93.225.1 371.9%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %1.00.2 448.4%  
Book value per share (Unadj.) Rs586.5274.3 213.9%  
Shares outstanding (eoy) m45.7589.50 51.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.62.8 164.4%   
Avg P/E ratio x25.3114.0 22.2%  
P/CF ratio (eoy) x21.435.7 60.0%  
Price / Book Value ratio x3.43.3 104.3%  
Dividend payout %25.425.5 99.7%   
Avg Mkt Cap Rs m91,27180,058 114.0%   
No. of employees `0002.62.5 104.9%   
Total wages/salary Rs m3,1434,341 72.4%   
Avg. sales/employee Rs Th7,484.811,325.8 66.1%   
Avg. wages/employee Rs Th1,195.01,731.4 69.0%   
Avg. net profit/employee Rs Th1,369.1280.1 488.9%   
INCOME DATA
Net Sales Rs m19,68528,394 69.3%  
Other income Rs m1,143941 121.5%   
Total revenues Rs m20,82829,334 71.0%   
Gross profit Rs m5,0033,965 126.2%  
Depreciation Rs m6631,540 43.0%   
Interest Rs m41,962 0.2%   
Profit before tax Rs m5,4791,403 390.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,87897 1,930.5%   
Profit after tax Rs m3,601702 512.8%  
Gross profit margin %25.414.0 182.0%  
Effective tax rate %34.36.9 494.4%   
Net profit margin %18.32.5 739.7%  
BALANCE SHEET DATA
Current assets Rs m24,16724,836 97.3%   
Current liabilities Rs m9,54418,993 50.3%   
Net working cap to sales %74.320.6 361.0%  
Current ratio x2.51.3 193.6%  
Inventory Days Days5571 77.6%  
Debtors Days Days29113 25.3%  
Net fixed assets Rs m9,51434,289 27.7%   
Share capital Rs m458895 51.1%   
"Free" reserves Rs m26,37523,651 111.5%   
Net worth Rs m26,83224,546 109.3%   
Long term debt Rs m2515,513 0.2%   
Total assets Rs m36,90065,437 56.4%  
Interest coverage x1,305.51.7 76,123.3%   
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x0.50.4 122.9%   
Return on assets %9.84.1 239.9%  
Return on equity %13.42.9 469.1%  
Return on capital %20.46.9 296.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2215,697 0.1%   
Fx outflow Rs m1,489735 202.4%   
Net fx Rs m-1,46614,962 -9.8%   
CASH FLOW
From Operations Rs m3,3181,871 177.4%  
From Investments Rs m-2,3835,826 -40.9%  
From Financial Activity Rs m-1,104-10,157 10.9%  
Net Cashflow Rs m-169-2,615 6.4%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 37.8 19.8%  
FIIs % 4.9 8.6 57.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 25.9 91.5%  
Shareholders   85,207 56,241 151.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   AUROBINDO PHARMA  MERCK  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; Metal Stocks Lead(12:30 pm)

Stock markets in India are presently witnessing buying interest. The BSE Sensex is trading up by 95 points and the NSE Nifty is trading up by 38 points.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

The Best Trading Strategy in the World(Profit Hunter)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

Election Series: Why 'Liquor' is so Important to the Elections(The 5 Minute Wrapup)

Apr 19, 2019

When elections come around, liquor flows like water and everyone gets drunk with power...what does this mean for liquor stocks? Read one to find out from our very own election trading analyst, Vijay Bhambwani.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Apr 26, 2019 03:05 PM

TRACK PFIZER

PFIZER - UNICHEM LAB COMPARISON

COMPARE PFIZER WITH

MARKET STATS